Cannabis recorded for 84% of teenagers receiving substance-related emergency care in US study
US insurance records reveal marked age differences, but a cannabis diagnosis did not necessarily explain why a patient needed hospital treatment.
Cannabis appeared in the diagnoses of 84% of teenagers who received substance-related emergency care in a large US study, but researchers cautioned that its presence did not necessarily mean it caused the admission.
The research found sharply different patterns by age: cannabis featured most prominently among younger patients, while alcohol dominated substance-related emergency care among older adults. Nearly half of the encounters involving cannabis also involved at least one other substance.
Published in the American Journal of Psychiatry, the study examined health insurance records for more than 1.3 million people aged 16 to 64 who had at least one substance-related emergency department visit or hospitalisation between January 2016 and December 2023. Together, they accounted for more than five million encounters.
The records came from large commercial insurance and Medicaid databases and covered opioids, stimulants and other addictive substances as well as alcohol and cannabis. Researchers divided patients into six age groups: 16–18, 19–24, 25–34, 35–44, 45–54 and 55–64.
Among patients aged 16 to 18, 84% had at least one encounter involving cannabis, compared with 19% of those aged 55 to 64. These figures describe people already receiving substance-related emergency care, not the wider population.
Young adults aged 19 to 24 recorded the largest increase in the proportion of encounters involving cannabis over the eight-year study. Among teenagers, that proportion rose by about 0.8 percentage points a year, while older age groups showed little change.
There was, however, an important distinction between cannabis appearing in a diagnosis and being the main reason for admission. When researchers examined only hospitalisations in which cannabis was the primary reason, the trend among adolescents declined. That suggests its increasing presence in acute care records did not necessarily make it the sole driver of hospitalisation, which often involved other substances.
Study leader Dr Kevin Xu, an assistant professor of psychiatry at Washington University School of Medicine in St. Louis, explained that the analysis counted any encounter in which cannabis appeared anywhere on the diagnosis list. The visit could have concerned a car accident injury, a psychiatric crisis or an unrelated medical problem.
Xu nevertheless warned that the risks of cannabis are often oversimplified and underestimated, particularly as stronger products become readily available. He said increasing potency made it easier to consume far more THC, the psychoactive ingredient in cannabis, than in the past.
A recent study suggested that cannabis use disorder becomes more likely above roughly 40 milligrams of THC a week in adults and 30 milligrams in adolescents.
Xu said high-potency products posed particular risks during the critical periods of brain development experienced by adolescents and young adults. Heavy teenage use has also been associated with a greater risk of psychotic symptoms, although most people who use cannabis do not experience these problems.
Many regular users do not need emergency care. Even so, the researchers identified concerning increases in cannabis-related admissions involving psychosis and severe vomiting among younger people.
Alcohol presented a different pattern. Despite an overall decline in US alcohol use during the study period, alcohol-related emergency care and hospital admissions remained high and generally increased with age. Among adolescent patients, 33% had an alcohol-related encounter, rising to 70% among those aged 55 to 64.
The steepest increase in any trend examined was in alcohol as the primary reason for hospitalisation among adults aged 25 to 34.
First author Dr Jacob Steinle said: “There are many lingering questions to answer, especially about understanding why substance use-related harm patterns vary so greatly across the lifespan.”
He said further research would aim to help clinicians give individual patients and the wider public better information about substance-use risks.